What Must The U.S. Do To Bolster Its High-Tech Industries?

A recent [Department of Defense] report defines technology transfer as the transition of R&D programs from research to application by a user. It begins when an R&D agency shows the users, early in the planning stage of a project, how a technology can be applied to their needs. Based on that definition, there is very little evidence of technology transfer from federal agencies to the industrial sector.... Despite the fact that the U.S. makes major investments in R&D, the results are not reflect

Written byJeffrey Mervis
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

A recent [Department of Defense] report defines technology transfer as the transition of R&D programs from research to application by a user. It begins when an R&D agency shows the users, early in the planning stage of a project, how a technology can be applied to their needs. Based on that definition, there is very little evidence of technology transfer from federal agencies to the industrial sector....

Despite the fact that the U.S. makes major investments in R&D, the results are not reflected in our having a competitive advantage in the marketplace. The first thing to be recognized is that it is not the mission of federally funded agencies to focus on research and development that generate competitive products. That change in focus would require a policy of "market pull," where the product objectives simultaneously take into account both military and commercial product requirements.

The present allocation of resources have ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies